Panwen Wang

Panwen Wang

Auto-generated profile, based on publicly available information

Panwen Wang

Department of Quantitative Health Sciences, Mayo Clinic, Phoenix, AZ, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2016 in Bioinformatics
Verified
Journal Article
Open access
PDF file
MLMulin Jun Li
Mulin Jun Li
ZPZhicheng Pan
Zhicheng Pan
ZLZipeng Liu
Zipeng Liu
JWJiexing Wu
Jiexing Wu
PWPanwen Wang
Panwen Wang
JWJunwen Wang
Junwen Wang
Motivation: Prediction and prioritization of human non-coding regulatory variants is critical for understanding the regulatory mechanisms of disease pathogenesis and promoting personalized medicine. Existing tools utilize functional genomics data and evolutionary information to evaluate the pathogenicity or regulatory functions of non-coding variants. However, different algorithms lead to inconsistent and even conflicting predictions. Combining multiple methods may increase accuracy in regulatory variant prediction. Results: Here, we compiled an integrative resource for predictions from eight different tools on functional annotation of non-coding variants. We further developed a composite strategy to integrate multiple predictions and computed the composite likelihood of a given variant being regulatory variant. Benchmarked by multiple independent causal variants datasets, we demonstrated that our composite model significantly improves the prediction performance. Availability and Implementation: We implemented our model and scoring procedure as a tool, named PRVCS, which is freely available to academic and non-profit usage at http://jjwanglab.org/PRVCS. Contact:wang.junwen@mayo.edu, jliu@stat.harvard.edu, or limx54@gmail.com Supplementary information: Supplementary data are available at Bioinformatics online.

1 October 2022 in The Anatolian Journal of Cardiology
Verified
Journal Article
Open access
NVNithin R. Venepally
Nithin R. Venepally
RAReza Arsanjani
Reza Arsanjani
PAPradyumna Agasthi
Pradyumna Agasthi
PWPanwen Wang
Panwen Wang
Banveet KaurBanveet Kaur
Banveet Kaur
FMFarouk Mookadam
Farouk Mookadam
Antiphospholipid syndrome,Libman-Sacks endocarditis,marantic endocarditis,nonbacterial thrombotic endocarditis,systemic lupus erythematosus

1 January 2020 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
PAPradyumna Agasthi
Pradyumna Agasthi
SPSai Harika Pujari
Sai Harika Pujari
FMFarouk Mookadam
Farouk Mookadam
ATAndrew Tseng
Andrew Tseng
NVNithin R. Venepally
Nithin R. Venepally
RAReza Arsanjani
Reza Arsanjani
Agasthi P, et al. Yonsei Med J. 2020 Jun;61(6):482-491. https://doi.org/10.3349/ymj.2020.61.6.482

7 October 2025 in Cancer Prevention Research
Verified
Journal Article
Open access
CMCaroline L. Matchett
Caroline L. Matchett
SSSeth W. Slettedahl
Seth W. Slettedahl
WTWilliam R. Taylor
William R. Taylor
CBCalise K. Berger
Calise K. Berger
CACaryn E. Anderson
Caryn E. Anderson
JKJohn B. Kisiel
John B. Kisiel
Aberrant DNA methylation and copy-number alterations (CNA) drive Barrett’s esophagus progression to esophageal adenocarcinoma; however, their combined utility for early detection is unclear. We aimed to identify and validate methylated DNA markers (MDM) and CNAs to distinguish esophageal adenocarcinoma/high-grade dysplasia (HGD) from nondysplastic Barrett’s esophagus (NDBE). In this multiphase, multicenter study, we discovered and validated MDMs and quantified CNAs utilizing whole-genome methylation sequencing of esophageal brushings. DNA biomarkers identified from discovery were further validated in independent patients with paired esophageal brushing and swallowed capsule sponge samples. MDMs were filtered against a reduced representation bisulfite sequencing dataset obtained from independent tissue samples to advance only concordant candidates. CNA burden was quantified using ichorCNA-derived aneuploidy scores (AS). Two hundred MDMs discovered in HGD (N = 18) and esophageal adenocarcinoma (N = 18) versus NDBE brushing samples (N = 18) were tested in independent samples (N = 146). A 52-MDM panel achieved a cross-validated AUC of 0.88 [95% confidence interval (CI), 0.82–0.95]; the addition of AS improved discrimination of HGD/esophageal adenocarcinoma from NDBE to 0.91 (95% CI, 0.86–0.97) AUC. At 80% specificity, the combined model detected 93% of esophageal adenocarcinoma and 88% of HGD cases. In paired capsule sponge samples, a 58-MDM panel achieved a cross-validated AUC of 0.77 (95% CI, 0.66–0.88); a combined 58-MDM and AS model achieved AUC 0.80 (95% CI, 0.7–0.9). MDMs and AS discerned HGD/esophageal adenocarcinoma from normal esophagus/NDBE in endoscopic brushing and capsule sponge samples. This approach may improve Barrett’s esophagus surveillance. Prevention Relevance: This study demonstrates that combining epigenetic and genomic biomarkers across minimally invasive sampling methods can accurately distinguish HGD/esophageal adenocarcinoma from nondysplastic Barrett’s esophagus, offering promising, less invasive strategies to improve BE surveillance and enable endoscopic therapy for esophageal adenocarcinoma prevention and treatment.

29 March 2025 in NAR Genomics and Bioinformatics
Verified
Journal Article
Open access
PWPanwen Wang
Panwen Wang
YYYue Yu
Yue Yu
HDHaidong Dong
Haidong Dong
SZShuwen Zhang
Shuwen Zhang
ZSZhifu Sun
Zhifu Sun
YLYing Li
Ying Li
Single-cell sequencing technologies provide us with information at the level of individual cells. Combining single-cell RNA-seq and single-cell TCR-seq profiling enables the exploration of cell heterogeneity and T-cell receptor repertoires simultaneously. Integrating both types of data can play a crucial role in enhancing our understanding of T-cell-mediated immunity and, in turn, facilitate the advancement of immunotherapy. Here, we present immunopipe, a comprehensive and flexible pipeline to perform integrated analysis of scRNA-seq and scTCR-seq data. In addition to the command line tool, we provide a user-friendly web interface for pipeline configuration and execution monitoring, benefiting researchers without extensive programming experience. With its comprehensive functionality and ease of use, immunopipe empowers researchers to uncover valuable insights from scRNA-seq and scTCR-seq data, ultimately advancing the understanding of immune responses and immunotherapy development.

3 April 2026 in Science Advances
Verified
Journal Article
Open access
XZXingxing Zhu
Xingxing Zhu
YYYue Yu
Yue Yu
SCShiju Chen
Shiju Chen
HLHannah E. Langenfeld
Hannah E. Langenfeld
YLYanfeng Li
Yanfeng Li
HZHu Zeng
Hu Zeng
The underlying immunopathogenesis of inflammatory arthritis (IA) immune-related adverse event (irAE) remains obscure. Unlike rheumatoid arthritis (RA), where autoantibodies and B cell dysfunction are central features, the contribution of humoral immunity to IA-irAE is unclear. Here, we performed immunophenotyping of peripheral blood from patients with IA-irAE and compared them with patients with seronegative RA, immune checkpoint inhibition–treated patients without irAE, and healthy controls. IA-irAE was marked with increased cytotoxic gene expression and metabolic activation in T cells and reduced CXCR3 and CCR6 expression in CD4 + T cells. Contrary to seronegative RA, patients with IA-irAE displayed no substantial elevation in autoantibody levels or atypical CD11c + CD21 − B cells. IA-irAE was further characterized by elevated levels of interleukin-6 (IL-6), IL-12, and type I interferon, which correlated with the T cell activation phenotypes. Together, our findings define IA-irAE as a disease with certain immunological features distinctive from RA, representing a potentially T cell–driven, autoantibody-independent autoimmunity. These results offer insights into immune tolerance breakdown and therapeutic targeting in irAEs.